- Sangamo BioSciences (SGMO +19.4%) enjoys a nice pop today on double normal volume. Investors are sharing some love for the potential of bluebird bio's (BLUE +72.9%) LentiGlobin BB305 in beta-thalassemia. Sangamo has a collaboration with Biogen Idec to develop its ZFN-mediated gene modification technology in hemoglobinopathies such as sickle cell disease and beta-thalassemia.
- Previously: bluebird bio's LentiGlobin delivers impressive results in beta-thalassemia, shares jump (Dec. 9, 2014)
Sangamo rides bluebird's wave
Recommended For You
About SGMO Stock
Related Stocks
| Symbol | Last Price | % Chg |
|---|---|---|
| SGMO | - | - |
| Sangamo Therapeutics, Inc. | ||